Bullous Pemphigoid

Table of Contents

1. What Bullous Pemphigoid Is
2. Pathogenesis: BP180 and BP230 Autoantibodies
3. Clinical Features: Prodrome and Tense Bullae
4. Diagnosis: Biopsy, DIF, and ELISA
5. Differential Diagnosis: BP vs. Pemphigus Vulgaris
6. Drug Triggers and Gliptin-Associated BP
7. Neurological Associations
8. Treatment: Topical Steroids, Doxycycline, and Rituximab
9. Monitoring Disease Activity: BPDAI
10. Prognosis and Mortality in the Elderly
11. Key Research Papers
12. Connections
13. Featured Videos

What Bullous Pemphigoid Is

In plain words, the immune system attacks the anchors that hold the top layer of skin to the layer beneath it, and large, firm blisters form. It mostly affects people around 80 years old. The blisters are often preceded by weeks or months of intense itch and hive-like or eczema-like patches with no blisters at all, a stage commonly mistaken for hives, eczema, contact dermatitis or scabies.

Bullous pemphigoid (BP) is the most common autoimmune blistering disorder in the Western world, characterized by autoantibodies directed against proteins within the hemidesmosome — the molecular structure anchoring the outer layer of skin (epidermis) to the deeper layer (dermis). The resultant immune assault at the basement membrane zone (BMZ) cleaves the two layers apart, producing large, firm, tense blisters that stand in stark contrast to the fragile, easily ruptured blisters of pemphigus vulgaris.

Bullous pemphigoid is overwhelmingly a disease of the elderly. The mean age at diagnosis is approximately 80 years, with incidence rising steeply with age — a 2025 review gives 190–312 new cases per million people per year among people over 80, while the rate in those under 45 is less than 1 per million. Overall rates include 4.3 per 100,000 person-years in the United Kingdom (Langan 2008) and a pooled global figure of 34.2 per million person-years (Persson 2022). Incidence is increasing in Western countries, partly due to population aging and partly due to the growing use of dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) diabetes medications that can trigger BP. In the United Kingdom, one cohort (Langan 2008) found an average yearly increase of 17%, corresponding to a 4.8-fold increase over its 11-year study period; a 2013 Lancet review says reported incidence in Europe more than doubled in the previous decade.

Despite the absence of skin detachment (unlike Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) or pemphigus in severe cases), BP in the elderly carries significant morbidity and mortality. One-year mortality in elderly BP patients is about 20–40%; a pooled analysis of 25 studies and 4,594 patients put it at 23.5% (Kridin 2019). Much of this is attributed to comorbidities of advanced age rather than the blistering disease itself, yet a worldwide meta-analysis of 56 studies still put first-year deaths at 2.93 times the number expected in the general population (Tedbirt 2021). The chronic relapsing nature, the need for prolonged immunosuppression in an already frail population, and the association with underlying neurological disease all contribute to poor outcomes.

Pathogenesis: BP180 and BP230 Autoantibodies

Bullous pemphigoid is defined immunologically by immunoglobulin G (IgG) autoantibodies targeting two hemidesmosomal proteins:

BP180 (BPAg2 / Collagen XVII)

BP180 is a transmembrane collagen (type XVII) with an intracellular N-terminus within the basal keratinocyte and a long extracellular ectodomain that loops through the lamina lucida of the basement membrane. The pathogenically critical domain is the NC16A domain — the extracellular region immediately adjacent to the transmembrane anchor. Anti-BP180 NC16A antibodies are found in approximately 80–90% of BP patients and their titers correlate directly with disease activity, making them the most clinically useful serologic marker for diagnosis and monitoring.

Mechanistically, anti-BP180 immunoglobulin G binding activates complement (particularly C3 and C5a), recruits eosinophils and neutrophils to the dermal-epidermal junction (DEJ), and triggers the release of proteases (elastase, matrix metalloproteinase-9 (MMP-9)) from degranulating eosinophils that cleave the anchoring proteins of the BMZ, producing the subepidermal split. The eosinophilia in BP tissue and blood reflects this eosinophil-driven effector mechanism — a key histological feature that helps distinguish BP from other subepidermal blistering diseases.

BP230 (BPAg1)

BP230 is an intracellular plakin protein linking the hemidesmosome to the keratin intermediate filament cytoskeleton of basal keratinocytes. Anti-BP230 immunoglobulin G antibodies are found in approximately 60–70% of BP patients but are less directly pathogenic than anti-BP180, as BP230 is intracellular and less accessible to circulating antibodies. Anti-BP230 antibodies may amplify disease by disrupting hemidesmosomal structural integrity indirectly.

Immunological Cascade

The full mechanism from autoantibody to blister involves:

1. Immunoglobulin G anti-BP180 NC16A binding at the BMZ
2. Complement activation (C3a, C5a anaphylatoxins released)
3. Mast cell degranulation and eosinophil recruitment chemotaxis via interleukin-5, eotaxin
4. Eosinophil degranulation → elastase, matrix metalloproteinase-9, eosinophil cationic protein → proteolytic cleavage of BP180 extracellular domain and laminin 332
5. Subepidermal blister formation at the lamina lucida level

T-helper type 2 (Th2)-skewed immunity (elevated interleukin-4, interleukin-13, interleukin-31) is characteristic of BP, explaining the intense pruritus (interleukin-31 is a potent pruritogen) and peripheral eosinophilia. This T-helper type 2 skewing provides the mechanistic rationale for dupilumab (which blocks the interleukin-4 receptor alpha) and omalizumab (anti-immunoglobulin E) as BP therapies.

Clinical Features: Prodrome and Tense Bullae

Prodromal Phase (Weeks to Months)

A distinctive and often diagnostically confusing feature of BP is the prolonged prodromal phase — lasting weeks to months — during which patients experience intense pruritus and urticarial (hive-like) or eczematous skin changes without blisters. This "pre-bullous" BP is commonly misdiagnosed as chronic urticaria, eczema, contact dermatitis, or scabies. A 2026 review states that about 20% of patients present with non-bullous variants, such as persistent pruritic urticarial plaques — "non-bullous BP" or "urticarial phase BP." This makes diagnosis particularly challenging: in a series of 69 patients with non-bullous pemphigoid (Lamberts 2019), the mean delay in diagnosis was 29 months, and blisters later formed in 17%.

Classic Bullous Phase

When bullae develop, they are characteristically tense — thick-walled, firm, difficult to rupture with finger pressure — arising on an urticarial or erythematous base. The tenseness reflects the subepidermal location of the blister: the entire epidermis forms the blister roof, which is far more robust than the thin epidermal fragments that form the fragile roof of intraepidermal pemphigus blisters. Bullae are typically large (0.5–3 cm), filled with clear or blood-tinged fluid, and heal over days without scarring when they rupture (though milia may form at healing sites).

Distribution

BP preferentially involves the flexural surfaces and trunk:

• Inner thighs and groin
• Axillae
• Abdomen (especially the periumbilical area)
• Forearms and lower legs

The face, palms, soles, and scalp are less commonly involved (unlike pemphigus, where the scalp is frequently affected). Symmetric distribution is typical.

Mucous Membrane Involvement

In contrast to pemphigus vulgaris (where mucous membrane involvement is nearly universal and often the presenting feature), mucous membrane erosions occur in only approximately 20% of BP patients and are typically mild when present. Oral erosions are less painful and less disabling than in pemphigus. The relative sparing of mucous membranes in BP is explained by the predominance of BP180 at the cutaneous BMZ, with less expression in oral mucosal tissue.

Diagnosis: Biopsy, DIF, and ELISA

Skin Biopsy — Histology

Biopsy of an intact fresh bulla shows a subepidermal blister with a preserved, non-necrotic epidermal roof (contrast with Stevens-Johnson syndrome and toxic epidermal necrolysis, where the epidermis is necrotic). The blister cavity and the upper dermis contain abundant eosinophils — a key distinguishing feature of BP that helps differentiate it from other subepidermal blistering diseases (epidermolysis bullosa acquisita, dermatitis herpetiformis, linear immunoglobulin A (IgA) disease). Eosinophilic spongiosis in the epidermis adjacent to the blister is an additional supportive finding.

Direct Immunofluorescence (DIF) — Gold Standard

Perilesional skin biopsy stained with fluorescent anti-human antibodies reveals the pathognomonic linear immunoglobulin G and/or C3 deposition along the basement membrane zone. The linear band follows the dermal-epidermal junction continuously without the intercellular "fishnet" immunoglobulin G pattern seen in pemphigus. DIF sensitivity for BP is approximately 90%. Immunoglobulin G is present in 80–90% of cases; C3 is present in up to 95% and may be the sole positive finding in early disease.

Indirect immunofluorescence (IIF) on salt-split skin places the immunoglobulin G fluorescence on the epidermal (roof) side of the artificial blister — indicating that the antigen is located in the lamina lucida/upper BMZ, typical of BP. In contrast, epidermolysis bullosa acquisita (targeting type VII collagen in the sub-lamina densa) shows dermal-side immunoglobulin G on salt-split skin.

Enzyme-Linked Immunosorbent Assay (ELISA) — BP180 NC16A and BP230

Commercially available assays of this kind for anti-BP180 NC16A and anti-BP230 immunoglobulin G provide quantitative titers that:

• Aid diagnosis (anti-BP180 NC16A sensitivity approximately 83–89%, specificity approximately 98%)
• Correlate with disease activity — rising titers during tapering predict relapse
• Guide treatment decisions — sustained low/negative titers support medication reduction

BP can be diagnosed with confidence when clinical features, subepidermal histology with eosinophils, linear DIF at the BMZ, and a positive anti-BP180 blood test are all present.

BPDAI for Disease Quantification

The Bullous Pemphigoid Disease Area Index (BPDAI) was developed and validated as a standardized scoring tool to quantify disease extent for clinical trials and treatment monitoring. It scores blisters/erosions and urticarial/eczematous lesions separately, on skin and mucous membranes.

Differential Diagnosis: BP vs. Pemphigus Vulgaris

The most important clinical differential for BP is pemphigus vulgaris (PV). The distinction is clinically significant because the treatments, prognosis, and specific immunological mechanisms differ substantially:

• Blister character: BP blisters are tense and firm (subepidermal, intact epidermis as roof); PV blisters are flaccid and easily ruptured (intraepidermal, thin epidermal fragment as fragile roof)
• Nikolsky sign: Negative in BP (epidermis firmly attached to dermis outside blisters); Positive in PV (active acantholysis allows epidermal shearing in normal-appearing skin)
• Mucous membranes: Involved in nearly 100% of PV (often the presenting feature, months before skin); involved in only ~20% of BP (usually mild)
• Age: BP predominantly age 70–80+; PV most common in 40s–60s
• Histology split level: BP — subepidermal (below the epidermis); PV — suprabasal (within the epidermis, just above the basal layer)
• DIF pattern: BP — linear immunoglobulin G/C3 at BMZ; PV — intercellular "fishnet" immunoglobulin G throughout epidermis
• Dominant inflammatory cell: BP — eosinophils; PV — lymphocytes, minimal eosinophilia
• Target autoantigen: BP — BP180 NC16A, BP230 (hemidesmosomal); PV — Desmoglein 3, Desmoglein 1 (desmosomal)

Drug Triggers and Gliptin-Associated BP

Drug-induced BP is increasingly recognized, with the dipeptidyl peptidase-4 inhibitors (gliptins) — widely used for type 2 diabetes — emerging as the most significant drug class.

Dipeptidyl Peptidase-4 Inhibitors (Gliptins)

Sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin have all been associated with BP. Gliptin-induced BP has distinctive features that differentiate it from idiopathic BP:

• Predominantly non-inflammatory presentation — tense blisters on non-erythematous skin ("non-inflammatory BP"), rather than the typical urticarial base
• Histology shows less eosinophilic infiltrate than idiopathic BP
• In a 2022 multicenter series of 74 patients (Salemme 2022), immunoglobulin G, immunoglobulin E and immunoglobulin A responses to both BP180 and BP230 were reduced in frequency and titers compared with idiopathic BP, and immunoglobulin G targeted BP180 regions other than NC16A
• Improvement typically follows gliptin discontinuation, though treatment with topical/systemic steroids is usually still required

The proposed mechanism: dipeptidyl peptidase-4 (CD26) is expressed on T regulatory cells and may alter immune tolerance at the dermal-epidermal junction; dipeptidyl peptidase-4 inhibition may disrupt this tolerance, unmasking autoreactive T-cell responses to BP antigens.

Other Implicated Drugs

• Furosemide: Loop diuretic associated with BP, particularly in elderly patients on chronic high-dose therapy
• Neuroleptics and antipsychotics: Chlorpromazine, risperidone, and other antipsychotics have been linked to BP
• Aldosterone antagonists (spironolactone): Case series associations
• Immune checkpoint inhibitors (programmed cell death protein 1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors): Pembrolizumab, nivolumab can trigger BP as an immune-related adverse event — an increasingly recognized association as checkpoint inhibitors are used more broadly in oncology

Neurological Associations

A striking and now well-established feature of BP is its association with neurological diseases. Approximately 25–35% of BP patients have a concurrent neurological condition, predominantly:

• Dementia (Alzheimer's disease and other dementias)
• Parkinson's disease
• Stroke (cerebrovascular accident)
• Epilepsy
• Multiple sclerosis

A 2016 meta-analysis of 14 case-control and cohort studies (Lai 2016; 23,369 people with BP and 128,697 controls) found people with BP more likely to have stroke (relative risk 2.68), Parkinson's disease (3.42), dementia (4.46), epilepsy (2.98) and multiple sclerosis (12.40) than controls.

This association is not explained by age alone (elderly patients have higher rates of neurological disease, but the BP–neurological association persists after age-matching). The leading hypothesis is a cross-reactive autoimmune mechanism: the BP180 and BP230 proteins have neuronal isoforms expressed in the brain (neuronal BP180 and dystonin/BPAG1-n). In patients with neurological disease, damage to the blood-brain barrier may expose these neuronal autoantigens, generating autoantibodies that cross-react with the skin isoforms of the same proteins, triggering BP as a secondary bystander phenomenon.

What this means in practice: an older person with new BP has a raised chance of an underlying neurological condition, and a new itchy rash in someone with dementia or Parkinson's disease can be bullous pemphigoid, even before any blister appears.

Treatment: Topical Steroids, Doxycycline, and Rituximab

First-Line: High-Potency Topical Corticosteroids

The 2022 European guideline names high-potency topical corticosteroids (e.g., clobetasol propionate 0.05% cream) as "the mainstay of treatment whenever possible" and oral prednisone 0.5 mg/kg/day as an alternative. They are the preferred first-line treatment particularly in the elderly, where systemic corticosteroids carry significant toxicity. The landmark 2002 randomized controlled trial (RCT) by Joly and colleagues (341 patients) compared clobetasol propionate cream, 40 g a day applied to the entire body surface, with oral prednisone. In the 188 patients with extensive disease the cream did better: one-year survival 76% vs 58%, disease control at 3 weeks 99% vs 91%, and severe complications (diabetes, infection, sepsis) 29% vs 54%. In the 153 patients with moderate disease there were no significant differences in survival, control or severe complications. This was a paradigm shift from reflexive systemic steroid use.

For extensive BP (large body surface area involvement), applying cream to the whole body can be impractical, and oral corticosteroids (prednisone 0.5 mg/kg/day) are used with the goal of rapid tapering, even though the extensive-disease group in that trial did better on the cream. The concern in the elderly is the toxicity of systemic corticosteroid exposure.

Doxycycline Plus Niacinamide

The combination of doxycycline (100 mg twice daily) plus niacinamide (500 mg three times daily) has anti-inflammatory activity via matrix metalloproteinase inhibition and anti-eosinophilic mechanisms. The main randomized trial tested doxycycline alone, not this combination: Williams 2017 (253 patients, 54 UK and 7 German centres) compared doxycycline 200 mg a day with prednisolone 0.5 mg/kg/day. At 6 weeks, 74% vs 91% had three or fewer blisters, an adjusted difference of 18.6% favouring prednisolone that fell within the trial's pre-set 37% non-inferiority margin. Severe, life-threatening or fatal treatment-related events by 52 weeks were 18% vs 36%. A 2026 review sums this up as doxycycline being effective, "although significantly less than" prednisolone. Doxycycline is used as a systemic option particularly for frail elderly patients where steroid side effects are the primary concern; the 2022 European guideline calls the use of doxycycline and dapsone "controversial" and says they may be recommended, in particular for patients with contraindications to oral corticosteroids.

Steroid-Sparing Adjuvants

• Dapsone: For patients with predominantly urticarial (pre-bullous) BP or as adjuvant to reduce steroid requirement; anti-eosinophilic mechanism. Requires glucose-6-phosphate dehydrogenase (G6PD) screening.
• Azathioprine (1–2 mg/kg/day): Traditional steroid-sparing agent; requires thiopurine S-methyltransferase (TPMT) enzyme testing. Slow onset (8–12 weeks).
• Mycophenolate mofetil (1–3 g/day): Alternative antimetabolite adjuvant; better tolerated than azathioprine in some patients.
• Methotrexate (low-dose weekly): Useful in elderly with contraindications to other agents; folate supplementation required.

A 2026 open-label randomized trial (Dereure 2026; 266 patients, mean age 80.8) compared one month of clobetasol followed by low-dose methotrexate with prolonged clobetasol alone. Nine-month survival was 86.5% vs 83.5%, and relapse-free survival 68.4% vs 47.4%, but severe adverse events were more frequent with methotrexate (0.40 vs 0.19 per patient per month).

Rituximab for Refractory BP

Rituximab (anti-CD20 B-cell depletion) has shown efficacy in refractory or corticosteroid-dependent BP uncontrolled with conventional agents. Given the pathogenic role of immunoglobulin G autoantibodies, the mechanistic rationale mirrors its use in pemphigus vulgaris. Dosing protocols (1000 mg intravenous (IV) on days 1 and 15, or 375 mg/m² ×4 doses) have produced sustained remissions in case series and small cohort studies. A 2022 systematic review of 122 rituximab-treated patients (Cao 2022) reported complete remission in 70.5%, recurrence in 20.5% and deaths in 9.0%. A 2026 review says rituximab data in BP are based on case series and that it "will foreseeably not be investigated" in randomized trials.

Newer Biologics

• Dupilumab (blocks the interleukin-4 receptor alpha): Given the T-helper type 2 skewing of BP, dupilumab has shown promise in case series for refractory or recurrent BP, particularly the urticarial/non-inflammatory subtype; a meta-analysis of 5 non-randomized studies (Mainville 2025; 167 participants) linked it to shorter time to disease control, with the evidence graded very low. The current US drug label (version dated April 22, 2026) lists it "for the treatment of adult patients with bullous pemphigoid," used with a tapering course of oral corticosteroids; a 2026 review dates the FDA approval to June 2025. In the trial described on the label (ADEPT, 106 adults, all also on oral corticosteroids), sustained remission at week 36 was reached by 18.3% on dupilumab vs 6.1% on placebo (difference 12.2 points; 95% confidence interval −0.8 to 26.1), and itch fell by at least 4 points in 38.3% vs 10.5%. A 2025 review calls the effect "rather modest" and limited to a patient subgroup, and says strategies aimed at eosinophils, including benralizumab, failed.
• Omalizumab (anti-immunoglobulin E): Immunoglobulin E anti-BP180 antibodies have been described in BP; omalizumab has shown benefit in case reports of immunoglobulin E-mediated urticarial BP.
• FcRn inhibitors (efgartigimod, nipocalimab): Block the FcRn receptor that recycles immunoglobulin G → accelerated immunoglobulin G catabolism, lowering pathogenic anti-BP180 titers. The phase 2/3 trial of efgartigimod in BP (BALLAD, NCT05267600) ended in September 2024 and its long-term extension (BALLAD+, NCT05681481) was terminated by sponsor decision in March 2025; a 2026 review says that after the phase 2 part with 40 patients it was decided not to proceed with the phase 3 part. A ClinicalTrials.gov search found no nipocalimab trial in BP.

Monitoring Disease Activity: BPDAI

Monitoring BP during treatment requires both clinical and serological tools:

• BPDAI score: Formal tracking of blister/erosion counts and urticarial/eczematous lesions at each visit. Validated end points for clinical trials; enables objective documentation of response.
• Anti-BP180 NC16A antibody titers: Falling titers confirm serological response to treatment. Persistent elevated titers despite clinical remission ("serological" activity) may predict early relapse — consideration for more prolonged treatment.
• Blood eosinophil count: Correlates with disease activity in some patients; normalization supports treatment response.
• Clinical remission definitions (International Pemphigoid Committee): Complete remission off therapy (CROT) — absence of new or established lesions or itch for ≥2 months off all treatment; complete remission on therapy, also called on minimal therapy (CRMT) — absence of new or established lesions or itch for at least 2 months on minimal therapy, which the committee defines as up to 0.1 mg/kg/day of prednisone (or equivalent) or 20 g/week of clobetasol propionate and/or minimal adjuvant or maintenance therapy.

Prognosis and Mortality in the Elderly

BP in the elderly is associated with substantial mortality, though the blistering disease itself is not usually the proximate cause of death:

• One-year mortality for elderly BP patients ranges from about 20–40% in population studies; pooled across 25 studies and 4,594 patients it was 23.5% (Kridin 2019). The death rate is well above that of matched people without BP: in a UK cohort, one-year mortality was 19%, with 131.99 deaths per 1,000 person-years vs 61.86 in controls and an adjusted hazard ratio of 2.3 (Langan 2008). Pooled standardized mortality ratios are 2.93 at one year (Tedbirt 2021) and 3.6 overall (Kridin 2018)
• Excess mortality is attributed to: infections (particularly pneumonia and sepsis from denuded skin as portal of entry), treatment side effects (corticosteroid-related sepsis, hyperglycemia, falls, gastrointestinal (GI) bleeding), and underlying neurological comorbidities
• Disease relapse is common — approximately 30–50% of patients relapse within 3 years after stopping therapy; most respond to retreatment
• Quality of life is significantly impaired by pruritus, pain from skin erosions, sleep disruption, and activity limitations
• Better outcomes are associated with: early diagnosis (before extensive disease), avoidance of drug triggers (especially gliptins), use of topical rather than systemic corticosteroids, and treatment in specialist dermatology centers

Key Research Papers

Key peer-reviewed studies on bullous pemphigoid pathogenesis, diagnosis, and treatment. Each PMID link opens the study on PubMed.

1. Diaz LA, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest. 1990;86(4):1088-1094. — PubMed PMID: 1698819
2. Giudice GJ, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151(10):5742-5750. — PubMed PMID: 8228259
3. Joly P, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. — PubMed PMID: 11821508
4. Murrell DF, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479-485. — PubMed PMID: 22056920
5. Salemme A, et al. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study. J Am Acad Dermatol. 2022;87(1):56-63. — PubMed PMID: 35240229
6. Langan SM, et al. Bullous pemphigoid and pemphigus vulgaris — incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180. — PubMed PMID: 18614511
7. Mainville L, et al. Time to Disease Control with Dupilumab for Bullous Pemphigoid: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2025;105:adv43667. — PubMed PMID: 40423583
8. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(12):2007-2015. — PubMed PMID: 27599898
9. Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol. 2022;13:928621. — PubMed PMID: 35769474
10. Williams HC, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630-1638. — PubMed PMID: 28279484
11. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-332. — PubMed PMID: 23237497
12. Borradori L, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689-1704. — PubMed PMID: 35766904
13. Kasperkiewicz M, van Beek N, Schmidt E. Autoimmune Bullous Diseases: Therapeutic Update. Drugs. 2026;86(4):485-506. — PubMed PMID: 41729378
14. Olbrich H, Sadik CD. Emerging drugs for the treatment of bullous pemphigoid: what's new on the horizon? Expert Opin Emerg Drugs. 2025;30(3):169-178. — PubMed PMID: 40878514
15. Dereure O, et al. Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trial. Br J Dermatol. 2026;ljag094. — PubMed PMID: 41807108
16. Werth VP, et al. Bullous pemphigoid burden of disease, management and unmet therapeutic needs. J Eur Acad Dermatol Venereol. 2025;39(2):290-300. — PubMed PMID: 39297242
17. Persson MSM, et al. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol. 2022;186(3):414-425. — PubMed PMID: 34480482
18. Kridin K, Shihade W, Bergman R. Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. Acta Derm Venereol. 2019;99(1):72-77. — PubMed PMID: 29963683
19. Kridin K, et al. Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios. J Dermatol. 2018;45(9):1094-1100. — PubMed PMID: 29905389
20. Tedbirt B, et al. Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid: A Meta-analysis. JAMA Dermatol. 2021;157(4):421-430. — PubMed PMID: 33729430
21. Lamberts A, et al. Nonbullous pemphigoid: Insights in clinical and diagnostic findings, treatment responses, and prognosis. J Am Acad Dermatol. 2019;81(2):355-363. — PubMed PMID: 31009674

Curated PubMed topic searches:

1. PubMed: BP180 pathogenesis
2. PubMed: Gliptin-associated BP
3. PubMed: DIF diagnosis BP
4. PubMed: Topical steroids BP
5. PubMed: BP neurological
6. PubMed: Rituximab in BP
7. PubMed: BP elderly mortality
8. PubMed: Dupilumab in BP

Back to Table of Contents

Connections

• Dermatology
• Pemphigus Vulgaris
• Stevens-Johnson Syndrome
• Lichen Planus
• Psoriasis
• Eczema
• Contact Dermatitis
• Lupus
• Vitiligo
• Alzheimer's Disease
• Parkinson's Disease
• Type 2 Diabetes

Back to Table of Contents

Featured Videos